BioDelivery Sciences International, Inc. (BDSI): Price and Financial Metrics

BioDelivery Sciences International, Inc. (BDSI): $4.13

-0.03 (-0.72%)

POWR Rating

Component Grades













Add BDSI to Watchlist
Sign Up

Industry: Biotech


of 506

in industry


  • Quality is the dimension where BDSI ranks best; there it ranks ahead of 98.2% of US stocks.
  • BDSI's strongest trending metric is Momentum; it's been moving down over the last 47 weeks.
  • BDSI ranks lowest in Momentum; there it ranks in the 15th percentile.

BDSI Stock Summary

  • With a one year PEG ratio of 4.34, Biodelivery Sciences International Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than only 20.84% of US stocks.
  • Of note is the ratio of Biodelivery Sciences International Inc's sales and general administrative expense to its total operating expenses; 86.47% of US stocks have a lower such ratio.
  • In terms of twelve month growth in earnings before interest and taxes, Biodelivery Sciences International Inc is reporting a growth rate of 285.1%; that's higher than 91.63% of US stocks.
  • If you're looking for stocks that are quantitatively similar to Biodelivery Sciences International Inc, a group of peers worth examining would be BWEN, MHH, TEX, LAWS, and KE.
  • BDSI's SEC filings can be seen here. And to visit Biodelivery Sciences International Inc's official web site, go to

BDSI Valuation Summary

  • BDSI's price/earnings ratio is 11.2; this is 69.32% lower than that of the median Healthcare stock.
  • Over the past 233 months, BDSI's price/earnings ratio has gone up 13.8.
  • Over the past 233 months, BDSI's price/sales ratio has gone down 18.6.

Below are key valuation metrics over time for BDSI.

Stock Date P/S P/B P/E EV/EBIT
BDSI 2021-08-31 2.3 3.3 11.2 7.9
BDSI 2021-08-30 2.3 3.3 11.0 7.7
BDSI 2021-08-27 2.3 3.3 11.1 7.8
BDSI 2021-08-26 2.3 3.3 11.2 7.9
BDSI 2021-08-25 2.2 3.2 10.9 7.6
BDSI 2021-08-24 2.3 3.3 10.9 7.7

BDSI Growth Metrics

  • Its year over year net cashflow from operations growth rate is now at 45.94%.
  • Its 2 year net cashflow from operations growth rate is now at 167.35%.
  • Its 3 year price growth rate is now at 125.23%.
BDSI's revenue has moved up $122,085,000 over the prior 52 months.

The table below shows BDSI's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 164.069 40.319 33.88
2021-03-31 159.212 29.691 25.981
2020-12-31 156.471 24.981 25.711
2020-09-30 145.94 30.886 14.818
2020-06-30 136.803 20.435 5.789
2020-03-31 129.898 20.345 -6.506

BDSI's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • BDSI has a Quality Grade of A, ranking ahead of 98.22% of graded US stocks.
  • BDSI's asset turnover comes in at 0.683 -- ranking 41st of 677 Pharmaceutical Products stocks.
  • CYRX, ACOR, and REPH are the stocks whose asset turnover ratios are most correlated with BDSI.

The table below shows BDSI's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.683 0.855 0.451
2021-03-31 0.685 0.843 0.363
2020-12-31 0.708 0.842 0.381
2020-09-30 0.705 0.838 0.274
2020-06-30 0.708 0.827 0.160
2020-03-31 0.722 0.822 0.178

BDSI Price Target

For more insight on analysts targets of BDSI, see our BDSI price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $6.88 Average Broker Recommendation 1.43 (Moderate Buy)

BDSI Stock Price Chart Interactive Chart >

Price chart for BDSI

BDSI Price/Volume Stats

Current price $4.13 52-week high $4.99
Prev. close $4.16 52-week low $3.04
Day low $4.02 Volume 381,876
Day high $4.19 Avg. volume 895,271
50-day MA $3.78 Dividend yield N/A
200-day MA $3.86 Market Cap 407.21M

BioDelivery Sciences International, Inc. (BDSI) Company Bio

BioDelivery Sciences International, Inc. engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company was founded in 1997 and is based in Raleigh, North Carolina.

BDSI Latest News Stream

Event/Time News Detail
Loading, please wait...

BDSI Latest Social Stream

Loading social stream, please wait...

View Full BDSI Social Stream

Latest BDSI News From Around the Web

Below are the latest news stories about Biodelivery Sciences International Inc that investors may wish to consider to help them evaluate BDSI as an investment opportunity.

BioDelivery Sciences International Completes Acquisition of ELYXYB™ for Acute Migraine Treatment in the U.S. and Canada

Expands Portfolio and Establishes Growth Platform in Neurology The First and Only FDA-Approved, Ready-to-Use Oral Solution for the Acute Treatment of Migraine with or without Aura in Adults Commercial Launch Planned for Q1 2022 Investor Day on October 14, 2021 RALEIGH, N.C., Sept. 09, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with chronic conditions, announced today that it has complet

Yahoo | September 9, 2021

BioDelivery Sciences to Exhibit Three Scientific Posters Comparing BELBUCA® to Oxycodone at the PAINWeek 2021 Conference

RALEIGH, N.C., Sept. 07, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with chronic conditions, will showcase three scientific posters regarding BELBUCA® (buprenorphine buccal film), CIII at the PAINWeek 2021 Conference taking place September 7 – 11, 2021 at The Cosmopolitan of Las Vegas. The posters include: Risk Stratification of Respiratory Depression With Buprenorphine Buccal Film Vers

Yahoo | September 7, 2021

BioDelivery (BDSI) Up 3.2% Since Last Earnings Report: Can It Continue?

BioDelivery (BDSI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | September 3, 2021

BioDelivery Sciences to Participate in Upcoming Virtual Investor Conferences

RALEIGH, N.C., Sept. 03, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that Jeffrey Bailey, Chief Executive Officer, and Terry Coelho, Executive Vice President and Chief Financial Officer, will present and participate in one-on-one investor meetings at the H.C. Wainwright 23rd Annual Global Investment Conference taking pl

Yahoo | September 3, 2021

Market Cool On BioDelivery Sciences International, Inc.'s (NASDAQ:BDSI) Earnings

When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") above 18x, you may...

Yahoo | September 3, 2021

Read More 'BDSI' Stories Here

BDSI Price Returns

1-mo 18.00%
3-mo 13.46%
6-mo 7.27%
1-year 2.99%
3-year 47.50%
5-year 73.53%
YTD -1.67%
2020 -33.54%
2019 70.81%
2018 25.42%
2017 68.57%
2016 -63.47%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9097 seconds.